TAVR Chugging Along at 5 Years in SURTAVI Trial
Plus, data suggest that it is probably cost-effective in low-risk patients
Stay updated with breaking news from Van Mieghem. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Plus, data suggest that it is probably cost-effective in low-risk patients
Jeffrey Clemens, Parker Rogers The public and political pressure on vaccine developers and global regulatory approval agencies has never been higher. The world has been eagerly awaiting any – and all – developments regarding vaccines and therapeutics required to fight the current Covid-19 pandemic. While the demand side is willing to pay almost any price for an effective and fast solution, unfortunately neither the drug development nor the drug approval process is designed to deliver speed and safety free of trade-offs. The dilemma faced by the regulators is simple. If regulators rush t...